The Rise Of Vector Therapies In Genetic Disorder Treatment: A Key Factor Shaping the Future of the Viral And Non-Viral Vector Manufacturing Market in 2025

"Which drivers are expected to have the greatest impact on the over the viral and non-viral vector manufacturing market's growth?
The viral and non-viral vector manufacturing markets are anticipated to be spurred by the rising occurrence of genetic disorders. These disorders are entirely or partially the result of abnormalities in the usual DNA sequence. Viral vectors facilitate the delivery of therapeutic genes to specific cells, replacing or compensating for the faulty genes that instigate genetic disorders. Non-viral vectors are typically utilized in ex vivo gene therapy methods, which involve genetic modification of cells outside the body before reintroducing them into the patient. As an example, data from the International Diabetes Federation, a diabetes federation based in Belgium, revealed in June 2022 that diabetes prevalence had climbed to 10.5% globally. Over half (44.7%) of these cases remain undiagnosed, and it's projected that by 2045, one in eight people, or approximately 783 million adults, will have diabetes. As such, the escalating incidence of genetic disorders propels the expansion of the viral and non-viral vector manufacturing market.

Get Your Viral And Non-Viral Vector Manufacturing Market Report Here:
https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

What is the future CAGR of the viral and non-viral vector manufacturing market, and how will it impact industry expansion?
The market size for manufacturing viral and non-viral vectors has seen a significant increase in the prior years. It is projected to rise from $8.67 billion in 2024 to a significant $10.3 billion in 2025, at a compound annual growth rate (CAGR) of 18.8%. This growth during the historic period was largely due to the escalating occurrence of genetic disorders, advancements in the field of biotechnology, heightened funding in gene therapy studies, increased consciousness surrounding personalized medicine, and regulatory backing for the advancement of gene therapy.

The market for manufacturing viral and non-viral vectors is predicted to undergo significant growth in the coming years, reaching a worth of $22.06 billion by 2029, with a compound annual growth rate (CAGR) of 21.0%. The expansion anticipated through the forecast period is due to factors such as an increase in demand for gene therapies, a broader scope of applications in treating rare diseases, enhanced investments in biomanufacturing infrastructure, and rising acceptance of precision medicine. Predominant trends during the forecast period comprise the creation of next-generation viral vectors, escalated use of CRISPR or cas9 technology in vector production, emphasis on scalable and cost-efficient manufacturing procedures, growing use of non-viral vectors, and advancements in manufacturing technologies for cell and gene therapy.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

What are the most significant trends transforming the viral and non-viral vector manufacturing market today?
The adoption of cutting-edge technologies is a primary trend gaining traction in the viral and non-viral vector manufacturing industries. Top companies in these sectors are introducing technologically innovative solutions to maintain their market stance. For example, in August 2022, Merck KGaA, a science and technology firm based in Germany, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. They are among the pioneer Contract development and manufacturing organizations and technology developers to provide a comprehensive viral vector production package, inclusive of AAV, Lentiviral, CDMO, CTO, and process development. This novel platform assists biopharmaceutical companies in reducing the cost and duration of process development while speeding up clinical manufacture.

Which key market segments comprise the viral and non-viral vector manufacturing market and drive its revenue growth?
The viral and non-viral vector manufacturing market covered in this report is segmented -

1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications

Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570

What regions are at the forefront of viral and non-viral vector manufacturing market expansion?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the leading players fueling growth in the viral and non-viral vector manufacturing market?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

What Is Covered In The Viral And Non-Viral Vector Manufacturing Global Market Report?

• Market Size Forecast: Examine the viral and non-viral vector manufacturing market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the viral and non-viral vector manufacturing market for a structured understanding.
• Key Players Overview: Analyze major players in the viral and non-viral vector manufacturing market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the viral and non-viral vector manufacturing market.
• Segment Contributions: Evaluate how different segments drive overall growth in the viral and non-viral vector manufacturing market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the viral and non-viral vector manufacturing market.
• Industry Challenges: Identify potential risks and obstacles affecting the viral and non-viral vector manufacturing market.
• Competitive Landscape: Review strategic developments in the viral and non-viral vector manufacturing market, including expansions, agreements, and new product launches.

"

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead

This release was published on openPR.